ML
ATNM icon

Mayport LLC’s Actinium Pharmaceuticals ATNM Stock Holding History

Mayport LLC’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.6K Hold
22,000
– – ﹤0.01% 133
2026
Q1 		$21.9K Hold
22,000
– – ﹤0.01% 130
2025
Q4 		$29.9K Hold
22,000
– – 0.01% 111
2025
Q3 		$35.2K Buy
+22,000
New +$35.8K 0.01% 109

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Mayport LLC's ATNM Position: Q2 2026 in Review

Mayport LLC held its Actinium Pharmaceuticals (ATNM) position steady in Q2 2026 at 22,000 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #133.

Mayport LLC first reported a position in ATNM in Q3 2025 and has held it in 4 quarters since. The position peaked at $35.2K in Q3 2025. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Mayport LLC held 22,000 shares of Actinium Pharmaceuticals worth $21.6K as of Q2 2026.
  • Mayport LLC left its Actinium Pharmaceuticals share count unchanged in Q2 2026.
  • Actinium Pharmaceuticals made up ﹤0.01% of Mayport LLC's portfolio in Q2 2026, its #133 holding.
  • Mayport LLC first reported a position in Actinium Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Mayport LLC's Actinium Pharmaceuticals position peaked at $35.2K in Q3 2025.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Mayport LLC's 13F filing for Q2 2026, filed 7 Aug 2026.